BonacaMPBauersachsRMAnandSS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med2020; 382: 1994–2004.
2.
GornikHLAronowHDGoodneyPP, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation2024; 149: e1313–e1410.
3.
SmahaLA; American Heart Association. The American Heart Association Get With The Guidelines program. Am Heart J2004; 148: S46–S48.
4.
CanonicoMEHsiaJHessCNBonacaMP.Sex differences in guideline-directed medical therapy in 2021–22 among patients with peripheral artery disease. Vasc Med2023; 28: 233–235.
5.
De CarloMSchlagerOMazzolaiL, et al. Antithrombotic therapy following revascularization for chronic limb-threatening ischaemia: A European survey from the ESC Working Group on Aorta and Peripheral Vascular Diseases. Eur Heart J Cardiovasc Pharmacother2023; 9: 201–207.
6.
MazzolaiLTeixido-TuraGLanziS, et al. 2024 ESC guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J2024; 45: 3538–3700.
7.
HessCNDaffronANehlerMR, et al. Randomized trial of a vascular care team vs education for patients with peripheral artery disease. J Am Coll Cardiol2024; 83: 2658–2670.
8.
LeeCRamkumarNYoungMN, et al. Therapeutic anticoagulation after index peripheral endovascular intervention in patients with claudication. J Vasc Surg2023; 78: 1461–1470.e2.
9.
RamkumarNGoodneyPPCreagerMAHenkinS.Association of anticoagulation and major adverse limb events after index peripheral endovascular intervention. Am J Cardiol2023; 192: 124–131.
